疾病活动与关节结构进展的分离在用菲尔戈提尼布治疗的风湿性关节炎患者中
Yoshiya Tanaka1, Tatsuya Atsumi2, Daniel Aletaha3
1First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan. tanaka@med.uoeh-u.ac.jp.
Rheumatology and therapy
|November 26, 2024
概括
在风湿性关节炎 (RA) 中达到临床缓解或低疾病活性,在24周内抑制关节损伤. 与安慰剂相比,菲尔戈蒂尼布200毫克 (FIL200) 也抑制了中度或高RA疾病活性患者的关节损伤.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 现代风湿性关节炎 (RA) 治疗的目标是缓解,但残留疾病活动对关节损伤的影响尚不清楚.
- 本研究研究了用菲尔戈提尼布 (FIL) 治疗的RA患者临床疾病活性和结构性关节进展之间的联系.
研究的目的:
- 为了评估临床疾病活动水平与RA患者的结构性关节进展之间的关联,用菲尔戈蒂尼布 (FIL) 或阿达利穆马布治疗与安慰剂治疗.
- 为了确定菲尔戈蒂尼布 (FIL) 是否表现出中度至高疾病活性患者结构性关节损伤的优异抑制.
主要方法:
- 对FINCH 1试验 (NCT02889796) 的后期分析,该试验涉及RA患者对甲状腺酸 (MTX) 的反应不足.
- 患者被随机分配到FIL 200 mg (FIL200),FIL 100 mg (FIL100),阿达利木马布或安慰剂,所有这些都具有背景MTX.
- 根据CDAI疾病活动类别,从基线对修改的总夏普得分 (mTSS),侵蚀得分和关节空间缩小得分的变化在24周后进行了评估.
主要成果:
- 在24周,在所有治疗组中观察到mTSS的最小变化,这些患者实现了CDAI缓解或低疾病活性 (LDA).
- 在中度疾病活性 (MDA) 或高疾病活性 (HDA) 的患者中,FIL200与安慰剂相比显示出明显较低的mTSS变化.
- 这表明,在具有较高疾病活性的患者中,临床疾病活性和结构性进展与FIL200的潜在脱.
结论:
- 在所有评估的治疗方法中,实现RA临床缓解或LDA与关节破坏的抑制进展有关.
- 与安慰剂相比,在患有MDA或HDA的患者中,菲尔戈蒂尼布200毫克 (FIL200) 独特地抑制了关节损伤.
- 这些发现表明,在某些RA患者亚组中,FIL200可能会将临床疾病活动与结构性进展脱.
相关概念视频
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Inflammatory Bowel Disease IV: Pharmacological Management
113
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
113
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
Actin Filament Depolymerization
3.0K
Actin filaments (F-actin) are composed of actin subunits. The dissociation of actin monomers can occur from either end of F-actin. The rate of dissociation is faster from the minus-end or the pointed end, where the actin subunits exist with a bound ADP, together known as ADP-actin. The depolymerization of F-actin is aided by proteins, including the actin-depolymerizing factor (ADF) and cofilin family of proteins, gelsolin, and glia maturation factor (GMF).
In F-actin, the ADF/cofilin proteins...
In F-actin, the ADF/cofilin proteins...
3.0K


